R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.

Annals of Hematology
Sandra Bašić-KindaIgor Aurer

Abstract

Currently, there is no consensus regarding optimal front-line treatment for younger high-risk patients with large B cell lymphoma. American recommendations list only R-CHOP as standard, while European also include R-ACVBP and R-CHOEP14. We have been routinely using the latter regimen at our institution since 2011 and performed this retrospective real-life single-center study to analyze outcomes. Between September 2011 and April 2019, 66 newly diagnosed patients aged 18 to 60 years with B-large cell lymphoma and high-risk age-adjusted International Prognostic Index score were scheduled to receive 6 or 8 cycles of bi-weekly chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, etoposide, steroids, and rituximab (R-CHOEP14). After a median follow-up of 4.7 years, the estimated 3-year progression-free survival was 87% (95% CI 80-96%) and 3-year overall survival 90% (95% CI 83-98%). Grade ≥ 3 hematological side effects occurred in 83% and infectious in 41% of patients; one patient died of toxicity. Grade ≥ 2 cardiac toxicity occurred in 21% of patients, more frequently than previously reported. The cumulative 5-year risk of congestive heart failure with all-cause mortality as the competing risk was 17%. R-CHOEP14 is a ...Continue Reading

References

Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Nov 5, 2010·Pharmacogenetics and Genomics·Caroline F ThornRuss B Altman
Apr 12, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Aug 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grzegorz S NowakowskiThomas E Witzig
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H TillyUNKNOWN ESMO Guidelines Committee
Nov 26, 2015·EXCLI Journal·Alessandra MontecuccoGiuseppe Biamonti
Feb 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sergio CortelazzoAlessandro Rambaldi
Dec 7, 2018·British Journal of Haematology·Birte FriedrichsUNKNOWN German high-grade lymphoma Study Group
Mar 13, 2019·American Journal of Hematology·Yang Liu, Stefan Klaus Barta
Mar 23, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesUNKNOWN PHOENIX investigators
Apr 3, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L BartlettJohn P Leonard
Oct 14, 2019·European Journal of Haematology·Agata MalendaKrzysztof Warzocha

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.